It has been already shown and discussed that KRAS, TP53, and SMAD4 are the main genetic findings in pancreatic cancer and considering that most patients will have these genomic alterations it would be necessary bigger samples of patients to identify impact of the absence of these mutations in outcomes. Here, TP53 is linked to pancreatic neoplasm.